Kadono, Yoshifumi, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Kouji Izumi, Taiki Kamijima, Chikashi Seto, et al. “Favorable Response of Pembrolizumab As Second-Line Therapy for Advanced Urothelial Carcinoma With Only Small Lesions to Not Be Considered Measurable by RECIST”. Urology Journal 19, no. 03 (December 20, 2021): 202–208. Accessed July 8, 2026. https://journals.sbmu.ac.ir/urolj/index.php/uj/article/view/6652.